Genomics and Drug Discovery: a view from industry - Will Chen

A view from industry on mathematical and computational technologies, and analysis of genomics scale data for drug discovery and development in neurodegenerative and neuroinflammatory diseases.

Will Chen

Will is the Head of Computational and Systems Biology at Biogen. His group leverages mathematical and computational technologies, and analysis of genomics scale data for drug discovery and development in neurodegenerative and neuroinflammatory diseases. Prior to joining Biogen in 2016 to build up its systems biology capabilities, he was a faculty member at Harvard Medical School where he led the computational and analytics effort of the nascent multi-investigator HMS Laboratory of Systems Pharmacology that was devoted to developing and advancing quantitative therapeutic sciences, toxicology and regulatory sciences, working across a number of disease areas with investigators from experimental labs, research hospitals and biotech and pharma organizations. He completed his postdoctoral training at Harvard Medical School (HMS) in 2013 on large-scale nonlinear dynamical modeling of cancer signal transduction, and his PhD on theoretical biophysics of protein folding at Harvard University in 2006.

Hosted by Professor Paul M Matthews (p.matthews@imperial.ac.uk) Contact Dr Jennifer Podesta (j.podesta@imperial.ac.uk) to arrange to meet with the speaker

Find out more: http://www.imperial.ac.uk/deme... 

Founding funders

Latest tweets from @UKDRI

RT @UkdriL: We have organised a mini-symposium with @QuanterixSimoa on biomarker detection using #simoa technology on the 30th of July! Com…
23 Jul 2019 12:55

RT @DementiasUK: Do data researchers know about our hub of resources for #dementia #cohort studies? It's all in here @turinginst @CLOSER_UK
23 Jul 2019 12:29